Heidelberg

Heidelberg Pharma is a German clinical-stage biopharmaceutical company pioneering the development of Antibody Targeted Amanitin Conjugates (ATACs), a novel class of antibody-drug conjugates (ADCs). The company's proprietary ATAC platform utilizes amanitin—a highly potent toxin derived from the death cap mushroom—as its payload, which uniquely inhibits RNA polymerase II to induce cell death in both dividing and quiescent cancer cells. Its lead candidate, pamlectabart tismanitin (HDP-101), is a BCMA-targeting ATAC currently in Phase IIa clinical trials for relapsed or refractory multiple myeloma. Heidelberg Pharma's pipeline also includes preclinical and early clinical candidates targeting CD37, PSMA, and GCC for various hematological and solid tumors. The company leverages strategic partnerships, notably with Huadong Medicine and Takeda, alongside royalty monetization agreements to advance its innovative oncology portfolio.